Johnson & Johnson

Equities

JNJ

US4781601046

Pharmaceuticals

Real-time Estimate Cboe BZX 21:05:10 01/05/2024 BST 5-day change 1st Jan Change
151.2 USD +4.61% Intraday chart for Johnson & Johnson +2.05% -3.30%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Stocks rise after Fed rate decision, Powell press conference RE
Sector Update: Health Care Stocks Advance Wednesday Afternoon MT
Top Midday Stories: CVS Reports Q1 Earnings Miss, Lowers Outlook; ADP Q1 Earnings Top Estimates; J&J Proposes $6.5 Billion Settlement for Talc Lawsuits MT
Johnson & Johnson Seeks EU Approval for Ulcerative Colitis, Crohn’s Disease Drug MT
Nasdaq, S&P 500 fall as investors take cover before Fed decision RE
Johnson & Johnson Announces $6.48 Billion Plan for Unit to Resolve Ovarian Cancer Talc Claims MT
Guggenheim Adjusts Johnson & Johnson's Price Target to $160 From $167 MT
Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday MT
Sector Update: Health Care MT
Transcript : Johnson & Johnson - Special Call
Johnson & Johnson Announces $6.48 Billion Plan for Unit to Resolve Ovarian Cancer Talc Claims MT
Johnson & Johnson Announces Plan For Subsidiary to Resolve Ovarian Cancer Talc Claims MT
J&J advances $6.475 billion settlement of talc cancer lawsuits RE
Johnson & Johnson to Consolidate Business Segments Under UK Brand MT
Stryker lifts 2024 profit forecast on strong demand for medical devices, implants RE
Global markets live: Adidas, Mercedes, McDonalds, Eli Lilly, PayPal, MicroStrategy, Tesla... Our Logo
J&J, Bristol Myers lose challenges to US drug price negotiation program RE
Declared voting Results by Johnson & Johnson CI
J&J: positive CHMP opinion for lung cancer CF
Addex Therapeutics Shares Plunge Premarket on Epilepsy Study Failure DJ
Johnson & Johnson Says Europe's CHMP Recommends Approval of Rybrevant Plus Chemotherapy for Lung Cancer Treatment MT
Redburn Atlantic Adjusts Johnson & Johnson Price Target to $160 From $170 MT
Cidara Therapeutics Shares Surge 42% After Re-Acquiring Flu Asset DJ
Alvotech’s Simponi Biosimilar Candidate Shows Efficacy in Confirmatory Study MT
J&J: EU green light for Carvykti in multiple myeloma CF
Chart Johnson & Johnson
More charts
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals; - consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc. At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25). Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
144.6 USD
Average target price
173.3 USD
Spread / Average Target
+19.83%
Consensus
  1. Stock Market
  2. Equities
  3. JNJ Stock
  4. News Johnson & Johnson
  5. Johnson & Johnson : Morgan Stanley Downgrades Johnson & Johnson to Equalweight from Overweight, Keeps $187 Price Target